News

Does Sermorelin Cause Hair Loss? Evidence Review

Creator: Priya Raman, Health Writer
Published: 2026-09-06

Current evidence does not identify hair loss as a sermorelin side effect. Growth hormone and IGF-1 affect follicles, but that biology cannot explain why one person starts shedding.

Priya Raman, Health Writer September 6, 2026 6 min read

A woman with shoulder-length hair sits facing the camera on a spa bench holding a mug

The short version

A 12-month Geref study of 110 children described sermorelin as well tolerated and did not identify hair loss; an adult GHRH(1-29) study included only 11 men for six weeks, so rare or delayed effects remain uncertain.
IGF-1 stimulated growth in cultured human hair follicles, while other experiments show GH/IGF-1 interactions with androgen activity in skin; neither direction proves a sermorelin effect on adult scalp hair.
Telogen effluvium typically becomes visible about 3–4 months after a trigger such as illness, stress, surgery, rapid weight change or inadequate nutrition, so the date shedding begins can obscure the cause.
In a 2024 study of 140 weight-loss-associated telogen effluvium cases, mean weight loss was 15.21% at 3.54 kg per month; those averages are descriptive, not a threshold and not sermorelin data.
A provider can distinguish diffuse shedding from patterned, patchy, inflammatory or scarring loss and decide whether blood count, ferritin, iron, thyroid or selected nutrient testing fits the history.

Does sermorelin cause hair loss? Current evidence says it is not an established adverse effect. Hair loss was not identified in the published Geref trial or historical adverse-reaction summaries, and small studies of the same GHRH(1-29) sequence did not produce a hair-loss signal. That is reassuring, not conclusive: the studies were too small and short to rule out a rare effect in adults. If shedding begins during a new regimen, the timing deserves a review, but it does not prove sermorelin caused it.

The more likely explanations include telogen effluvium after illness, stress, rapid weight change or reduced nutrition; iron or thyroid problems; and pattern hair loss that happened to become visible at the same time.

Does sermorelin cause hair loss in clinical studies?

The best direct treatment record comes from Geref, the former branded sermorelin product. In a 1996 multicenter study, 110 children received GHRH(1-29) for up to one year. The investigators reported no adverse changes in the general biochemical or hormonal tests and described treatment as well tolerated; the report did not identify alopecia (Thorner et al., Journal of Clinical Endocrinology & Metabolism, 1996).

An adult study was much smaller. Eleven healthy men ages 64 to 76 received nightly GHRH(1-29) for six weeks, and the researchers reported no significant adverse effects (Vittone et al., Metabolism, 1997). Six weeks and 11 participants cannot settle a question about uncommon or delayed shedding. A historical review of pediatric sermorelin use identifies transient facial flushing and injection-site pain as the most commonly reported adverse events; it does not identify hair loss (Prakash and Goa, BioDrugs, 1999).

That absence means hair loss is not an established sermorelin adverse effect. It does not mean every later report is impossible. Trials can miss rare events, and the old Geref population does not match the adults who receive compounded sermorelin today. The broader sermorelin side-effects guide owns the full tolerability list.

What GH and IGF-1 biology says about hair

Sermorelin signals the pituitary to release growth hormone, which can raise insulin-like growth factor 1, or IGF-1. Hair follicles respond to that axis, but the response is not a simple on-off switch for scalp growth.

In cultured human scalp follicles, physiologic concentrations of IGF-1 stimulated follicle growth and helped prevent an early shift into a catagen-like resting state. Growth hormone itself had no direct effect in that experiment (Philpott et al., Journal of Investigative Dermatology, 1994). That is a useful mechanism finding. It is not evidence that sermorelin grows hair, prevents balding or changes shedding in living adults. No clinical trial has tested sermorelin as a hair treatment.

The axis also interacts with androgen biology. In a placebo-controlled study of 46 men with growth hormone deficiency, GH replacement increased sexual body-hair scores without increasing the calculated free androgen index (Blok et al., Clinical Endocrinology, 1997). In a separate cell experiment, IGF-1 increased 5-alpha-reductase activity in human scrotal skin fibroblasts, an enzyme step involved in making dihydrotestosterone (Horton et al., Endocrinology, 1993). Neither study used sermorelin or measured scalp loss. Together they show why a mechanistic claim can point toward follicle support and androgen activity at once, depending on tissue and genetics.

Why shedding can start during a new regimen

The calendar can be misleading. Telogen effluvium occurs when a physiological stress shifts more follicles from active growth into rest. Diffuse shedding commonly becomes visible three to four months after the trigger, so the relevant event may predate the first hair noticed in the shower by a season (Malkud, Journal of Clinical and Diagnostic Research, 2015).

Common triggers include fever or other illness, surgery, childbirth, major emotional stress, rapid weight loss, a sustained calorie or protein shortfall, iron deficiency, thyroid disease and some medication changes. A new peptide regimen may also begin alongside a stricter diet, harder training, disrupted sleep or another prescription. Any one of those can fit the timeline better than the peptide itself.

Weight change matters even outside GLP-1 treatment. A 2024 study of 140 people with weight-loss-associated telogen effluvium found average weight loss of 15.21% at 3.54 kilograms per month (Kang et al., Annals of Dermatology, 2024). Those averages are not a diagnostic threshold, and the study did not involve sermorelin. They simply show that rapid weight change is a documented hair-cycle stressor. This is also why readers often connect peptide treatment with the neighboring GLP-1 question; tirzepatide-associated hair loss has a different trial record and a strong weight-loss context.

How a provider separates coincidence from cause

The useful work starts with the pattern and timeline. Diffuse shedding from all over a normal-looking scalp fits telogen effluvium better than smooth bald patches, broken hairs, redness, scale or scarring. A widening part or receding hairline may point toward pattern loss that a temporary shed has made easier to see.

A provider can map the start of shedding against illness, surgery, weight change, food intake, stress, hormonal changes and every medication or supplement. Depending on that history and an examination, testing may include a complete blood count, ferritin and iron studies, thyroid function or selected nutrient levels. Testing is more useful than assuming that every case needs the same collection of hair supplements.

At Promise, a licensed provider reviews every request and not everyone qualifies. If compounded sermorelin is prescribed, the reviewing provider can reassess symptoms, relevant labs and whether continuing or changing the plan makes sense. Medication and dose decisions belong in that clinical review.

Would switching GH-axis compounds solve the problem?

There is no evidence that switching from sermorelin to CJC-1295 with ipamorelin treats shedding. The compounds signal the growth hormone axis in different ways, but no clinical hair-outcome trial establishes either approach as safer for scalp hair. A provider may compare them based on the treatment goal, tolerability and lab response; sermorelin versus CJC-1295 explains those distinctions without turning either compound into a hair therapy.

As of September 2026, no FDA-approved sermorelin product is currently marketed; the compounded formulation offered here is not FDA-approved. FDA kept Geref on its discontinued-products list after determining that its withdrawal was not for reasons of safety or effectiveness (Federal Register, 2013). That status is one input, not a marketing warning: a licensed provider may still prescribe a compounded formulation when appropriate, and that decision is between the patient and the doctor.

When hair loss needs a closer look

Contact the prescribing provider when shedding is sudden or heavy, continues for months, or appears with fatigue, weakness, cold intolerance, menstrual changes or substantial unplanned weight change. Patchy loss, eyebrow or body-hair loss, scalp pain, redness, scale, scarring, or many short broken hairs deserves a prompt examination because that pattern is not typical telogen effluvium.

A medication change does not immediately reset the hair cycle. Follicles that have already shifted into rest may shed later, so stopping on the basis of timing alone can fail to address the actual trigger. The narrow, evidence-based answer remains the useful one: sermorelin has no established hair-loss signal, but new shedding still deserves a real diagnosis rather than an assumption.

Common questions

Does sermorelin cause hair loss?

No clear evidence shows that sermorelin causes hair loss. Hair loss was not identified in the main published Geref treatment study or historical adverse-reaction summaries. That record is reassuring but limited because the studies were small, old and often involved children. New shedding during treatment should be evaluated for timing, pattern, nutrition, thyroid or iron problems, illness, stress and other medications.

Can sermorelin help hair grow?

It has not been shown to grow hair in clinical trials. IGF-1 stimulated growth and delayed a resting-state change in cultured human follicles, but a laboratory follicle experiment is not a sermorelin treatment study. No human trial has established that sermorelin prevents shedding, restores scalp density or treats androgenetic hair loss, so hair growth should not be presented as an expected treatment result.

Why might hair shedding start after beginning sermorelin?

The overlap may be coincidental or reflect another change made at the same time. Telogen effluvium often appears three to four months after illness, surgery, emotional stress, rapid weight loss or inadequate energy, protein or iron intake. Thyroid disease, pattern hair loss and other medications can also fit. A provider can reconstruct that earlier timeline instead of assuming the newest prescription is automatically the cause.

What can a provider check for new hair loss?

A provider can examine whether loss is diffuse, patterned, patchy, inflamed or caused by breakage, then review the preceding months for illness, stress, diet, weight change and medication changes. Depending on those findings, testing may include a complete blood count, ferritin and iron studies, thyroid function or selected nutrients. Patchy or scarring patterns and persistent unexplained shedding may warrant a dermatology referral.

Should I stop sermorelin if my hair is shedding?

A medication change should be made with the prescribing provider. Stopping may not end shedding immediately because the hair cycle has a delay, and it may leave an iron, thyroid, nutrition or scalp condition unaddressed. The provider can compare the timing and pattern with the treatment goal, symptoms and laboratory results, then decide whether continuing, adjusting or changing the plan is appropriate.

Is sermorelin hair loss the same as GLP-1 hair loss?

Not based on the available evidence. Tirzepatide and other GLP-1-related treatments have a trial record of hair-loss reports in a setting of substantial weight reduction, where telogen effluvium is a leading explanation. Sermorelin is a GHRH analog, not a GLP-1 medication, and its clinical record has not identified the same signal. Both situations still require evaluation of competing causes.